Astellas Pharma
Global pharmaceutical company with commercial and development programs spanning oncology, ophthalmology, women's health, urology, and rare diseases.
Therapeutic areas
Selected products and programs
Linked curated drug profiles
Nectin-4-directed antibody-drug conjugate
enzalutamideSmall molecule androgen-receptor inhibitor
fezolinetantSmall molecule neurokinin-3 receptor antagonist
zolbetuximabCLDN18.2-directed monoclonal antibody
Selected active clinical trials
Phase 3 · Recruiting · Chronic Kidney Disease
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric CancerPhase 3 · Recruiting · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic CancerPhase 3 · Recruiting · Pancreatic Cancer
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)Phase 3 · Recruiting · Urothelial Cancer
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPhase 3 · Recruiting · Non-small Cell Lung Cancer (NSCLC)
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric CancerPhase 3 · Recruiting · Gastric Adenocarcinoma
Selected patent records
enzalutamide · Expires 2026-05-15
US 8183274enzalutamide · Expires 2026-08-24
US 8236773avacincaptad pegol sodium · Expires 2026-11-11
US 7579456avacincaptad pegol sodium · Expires 2027-02-14
US 9617546avacincaptad pegol sodium · Expires 2027-02-14
US 7709517enzalutamide · Expires 2027-08-13
Primary and company sources
Company and pipeline information can change. Verify material decisions against the linked primary sources.
Evidence & limits
Source: Open the source record
- Record identifier
- /companies/astellas-pharma/
- Event / action date
- Not separately retained
- Source update date
- Not separately retained
- Platform retrieval / processing date
- Not separately retained
What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.
Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.
Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.